Complications Related to Transarterial Treatment of Hepatocellular Carcinoma: A Comprehensive Review

Lee, Hyoung Nam; Hyun, Dongho

doi:10.3348/kjr.2022.0395

Cited by 8 publications

(1 citation statement)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The calculated total lung dose should be kept to less than 30 Gy for a single treatment, and less than 50 Gy for cumulative treatments, to avoid radiation pneumonitis. 28…”

Section: Risks and Side Effect Profilementioning

confidence: 99%

Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma

Behzadi,

Haghani,

D'Souza

et al. 2024

Semin intervent Radiol

View full text Add to dashboard Cite

Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) are common liver-directed therapies (LDTs) for unresectable HCC. While both deliver intra-arterial treatment directly to the site of the tumor, they differ in mechanisms of action and side effects. Several studies have compared their side effect profile, time to progression, and overall survival data, but often these lack practical considerations when choosing which treatment modality to use. Many factors can impact operator's choice for treatment, and the choice depends on treatment availability, cost, insurance coverage, operator's comfort level, patient-specific factors, tumor location, tumor biology, and disease stage. This review discusses survival data, time to progression data, as well as more practical patient and tumor characteristics for personalized LDT with TACE or TARE.

show abstract

“…The calculated total lung dose should be kept to less than 30 Gy for a single treatment, and less than 50 Gy for cumulative treatments, to avoid radiation pneumonitis. 28…”

Section: Risks and Side Effect Profilementioning

confidence: 99%